Effects of SGLT2 Inhibitors in Pre-heart Failure Populations With Hypertension
Status:
Recruiting
Trial end date:
2024-12-31
Target enrollment:
Participant gender:
Summary
In this multicenter, randomized, placebo-controlled trial in pre-heat failure patients with
hypertension and without diabetes, we will enroll 120 eligible patients to randomized to
receive placebo or engagliflozin (10mg/d) for follow them for 6 months. The primary endpoint
is the left atrial volume index, which reflects left ventricular diastolic function. We
sought to comprehensively evaluate the effect of engagliflozin on the structure and function
and explore its underlying mechanisms.